US2016235846A1PendingUtilityA1
Control of Blood Vessel Physiology To Treat Skin Disorders
Est. expiryJun 11, 2028(~1.9 yrs left)· nominal 20-yr term from priority
A61K 36/8969A61P 17/00A61K 31/455A61K 31/522A61K 36/752A61K 31/4164A61K 36/886A61K 36/28A61K 31/4166A61N 7/00A61K 31/137A61K 31/401A61K 36/14A61K 31/198A61K 36/88A61K 36/62A61K 31/295A61K 36/16A61K 31/17A61K 36/53A61K 41/0028A61N 5/062A61K 36/9068A61M 37/00A61K 31/425A61K 36/734A61K 9/0014A61K 36/185
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.
Claims
exact text as granted — not AI-modified1 . A method for treating an affected skin region of a patient having a skin disorder, the method comprising: a) applying a vasodilation composition to an affected skin region of a patient, said affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, wherein said blood vessel comprises a tissue architecture, b) waiting for a time sufficient to allow vasodilation of said at least one abnormal blood vessel in said affected skin region; c) non-invasively disrupting the tissue architecture of said vasodilated at least one abnormal blood vessel; and d) subsequent to disrupting the tissue architecture, applying a vasoconstriction composition to the affected skin region so as to cause vasoconstriction and collapse of the at least one abnormal blood vessel.
Join the waitlist — get patent alerts
Track US2016235846A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.